Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: F. Stephen Hodi, Michael Andrew Postow, Jason Alan Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P Linette, Nicolas Meyer, Jeffrey K. Giguere, Sanjiv Agarwala, Montaser F. Shaheen, Marc S. Ernstoff, David R. Minor, April K. Salama, Matthew H. Taylor, Patrick Alexander Ott, Joel Jiang, Paul Gagnier, Jedd D. Wolchok
Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Louisville, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Institut Gustave Roussy, University of Utah, Huntsman Cancer Institute, Beth Israel Deaconess Medical Center, Washington University in St. Louis, Institut universitaire du cancer de Toulouse Oncopole, Prisma Health, Temple University, UNM Comprehensive Cancer Center, Cleveland Clinic, California Pacific Medical Center, Duke University, Oregon Health & Science University, Bristol-Myers Squibb (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2516112263